Dipharma Francis S.r.l.

Cell Therapeutics, Inc.

Cell Therapeutics, Inc. - Sede Secondaria

Marco Artico

Pietro Allegrini

Emanuele Attolino

Gabriele Razzetti

Marc J McKennon

Mario Grugni

Gianluca Pardi

Giovanni Da Re

Luca Feliciotti

Pietro Allergrini

Marc Mckennon

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

Process for the preparation of fesoterodine or a salt thereof

Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate.

Process for the preparation of fesoterodine with low impurities content

The invention relates to an improved process for the preparation of poly-&#x3b1;-glutamic acids which comprises the polymerization of tertiary &#x3b3;-esters of &#x3b1;-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-&#x3b1;-glutamic acid-&#x3b3;-ester. The process is particularly advantageous in that it allows one to carefully control the molecular weight of the resulting poly-&#x3b1;-glutamic acid. The invention also relates to poly-&#x3b1;-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof.

Process for the preparation of poly-&#x3b1;-glutamic acid and derivatives thereof

Growing community of inventors

Parabiago, Italy

Marco Artico